What do we want from proteomics in the detection and avoidance of adverse drug reactions

Adverse Drug Reactions in Hospitalized Children in a Department of Infectious Diseases

“…The data analysis of the present study suggest a significant association between the number of medications received by children and the risk of an ADR. It was noted that patients with an ADR were taking significantly more medications than were patients without an ADR, which is consistent with findings of other authors 17,24 . Moreover, recently published investigations conducted in pediatric inpatients and outpatients show polypharmacy to be an important factor that predisposes patients to ADRs 11 .…”

“…It was noted that patients with an ADR were taking significantly more medications than were patients without an ADR, which is consistent with findings of other authors. 17,24 Moreover, recently published investigations conducted in pediatric inpatients and outpatients show polypharmacy to be an important factor that predisposes patients to ADRs. 11 The same results have been found in adult patients.…”

“…The causality relationship between the ADR and the suspected drug therapy was assessed case by case using the WHO Probability Scale (Table I). 17 A reaction's profile was made by calculating the number of reports of each system‐organ class of reaction as a percentage of all the reports. Severity was classified into 4 categories according to the following scheme: fatal, severe (directly life‐threatening and/or more than 1 month in duration, associated with organ‐system dysfunction, reduced life expectancy), moderate (some but not all of the mild criteria and none of the severe criteria) and mild (uncomplicated primary disease, no treatment required, and drug discontinuation not necessary) 12,18–20 .…”

How Proteomics Can Assist in the Detection and Avoidance of Adverse Drug Reactions

“…Adverse reactions are relatively common, accounting for as much as 15% of all hospital admissions [39], and serious adverse drug reactions resulting in death are estimated to occur in 0.32% of hospitalised patients. The diagnosis of these reactions remains difficult as they are idiosyncratic and host-dependent [40]. Because of this, it is appropriate to ask if proteomic technology can assist in the detection and avoidance of adverse drug reactions.…”

“…Because of this, it is appropriate to ask if proteomic technology can assist in the detection and avoidance of adverse drug reactions. Whilst this question has been explored previously [40], here we will discuss recent proteomic studies that have addressed some aspects of adverse drug reactions and how modern proteomics may assist their understanding and resolution.…”